MS MORGAN STANLEY Insider Trading

Morgan Stanley CLO Eric Grossman sold 11,118 shares for $2,120,758.50 on 2026-04-20 at blended $190.75, reducing holdings by 6.2%.

Eric Grossman, Chief Legal/Admin Officer, executed two separate sales totaling 11,118 shares for $2,120,758.50 on April 20, 2026, at prices of $190.00 and $191.50, leaving him with 169,402 shares post-transaction. The sales occurred near the 52-week high of $191.62, with current price at $190.70, positioning the trades within 0.5% of the yearly peak. Among his prior five sales at Morgan Stanley, only one was well-timed at the 90-day horizon; the most recent sale on January 20, 2026 showed a 90-day return of +3.6%, and his cross-ticker track record across six prior sells shows an average 90-day return of +5.6% with a 16.67% well-timed rate, indicating mixed execution timing historically. The company's fundamentals remain solid with $18.2B in quarterly revenue, 14.4% annual growth, and a P/E of 15.42, providing no obvious distress signal.

Morgan Stanley Co-President Saperstein sells 51,668 shares for $9,744,322.10 across 6 transactions on 2026-04-16

Andrew M Saperstein, Co-President of Morgan Stanley, executed 6 separate sales totaling 51,668 shares (51.7K shares) for $9,744,322.10 on 2026-04-16 at prices ranging from $187.20 to $192.12, representing a -15.5% reduction in his holdings from 333,810 to 282,142 shares. The sale occurred near the stock's 52-week high of $191.62 (current price $188.82 is -1.5% from that peak), and the blended average price of $188.59 exceeds the current price. Saperstein's prior 5 same-ticker sales at Morgan Stanley (all on 2026-01-20) showed negative 30-day returns averaging -5.4%, and his cross-ticker track record of 16 prior sells displays a 40.00% well-timed rate with average 90-day returns of -0.6%, indicating mixed historical accuracy in timing exits. This large concentrated sale merits observation as a material reduction of an insider's stake, though the execution at price levels close to recent resistance suggests opportunistic selling rather than forced liquidation.

Morgan Stanley CCO Mandell sells 16,129 shares for $3,035,754.61; retains 61,475 shares post-sale

Mandell executed 3 separate sales totaling 16,129 shares on 2026-04-16 at blended average price $188.22, reducing his stake by -20.8% from 77,604 to 61,475 shares. The current price of $188.82 is only -1.5% from the 52-week high of $191.62, indicating the sale occurred near the upper end of the stock's recent range. His cross-ticker track record shows 100.00% 90-day well-timed rate on 7 prior sells with average 90d return of -12.4%, but at Morgan Stanley specifically, his 5 prior sells in January 2026 averaged -5.3% over 30 days with no 90-day outcomes yet measurable. MS fundamentals remain solid: $18.2B quarterly revenue, $4.6B net income, +14.4% annual revenue growth, and P/E of 15.26 at $299.8B market cap. The context presents a material portfolio reduction by a senior executive near a 52-week high, executed through multiple tranches, though the stock's recent +18.8% 30-day performance and solid valuation metrics provide limited obvious fundamental distress signals.

Co-President Simkowitz sells 14,690 MS shares at $189.24; holds 365,802 post-transaction amid +18.8% 30-day rally.

Daniel A. Simkowitz, Co-President of Morgan Stanley, sold 14,690 shares for $2,779,987.02 on 2026-04-17 at $189.24, reducing holdings by 3.9% to 365,802 shares. This sale follows a strong 30-day gain of 18.8% in the stock and occurs near the 52-week high of $191.62. Across his prior trades at Morgan Stanley, Simkowitz achieved well-timed outcomes on 2 of 4 measurable 90-day intervals, with mixed results: his five prior MS transactions produced 90-day returns ranging from -22.5% to +15.2%. At the cross-ticker level, his historical sells have shown a 50% well-timed rate with an average 90-day return of -5.3%, suggesting modest predictive value in his market timing. The company's fundamentals remain solid—$4.6B net income, +14.4% annual revenue growth, and a P/E of 15.26—so the transaction itself does not indicate fundamental deterioration.

Co-President Simkowitz sold 32,968 shares of MS at $182.61 (Jan 30, 2026); holds 357,342 post-transaction.

Daniel Simkowitz, Co-President of Morgan Stanley, sold 32,968 shares for $6,020,312.85, reducing his holdings by 8.4% to 357,342 shares. The sale at $182.61 occurred when MS stock was trading 4.4% below its 52-week high of $191.23 and has since appreciated 3.0% over 30 days and 11.5% over 90 days. His prior sales at Morgan Stanley show a 40% well-timed rate at the 90-day mark (2 of 5 prior sells preceded declines), with mixed outcomes—two prior 2025 sales showed positive returns after sale (+2.5%, +3.5%), while two January 2025 sales preceded notable declines (-22.0%, -22.5%). Morgan Stanley's fundamentals remain solid with Q latest revenue of $18,224,000,000.00, net income of $4,610,000,000.00, and annual growth of +14.1%, trading at a P/E of 17.96. The transaction itself is moderate in scope relative to his total position, and timing outcomes at this ticker have been inconsistent.

CRO Charles Smith sells 8,500 MS shares at $182.08; retains 119.1K shares; cross-ticker track record shows poorly-timed sells.

Charles Smith, Morgan Stanley's Chief Risk Officer, sold 8,500 shares at $182.08 on 2026-01-20, reducing holdings by 6.7% to 119.1K shares. The sale occurred at a price 4.3% below the 52-week high of $191.23, while MS has gained 2.0% in the past 30 days and 11.7% over 90 days. Smith's cross-ticker track record across 2 prior sells shows an average 90-day return of 16.9%, with a 0.00% well-timed rate—indicating his prior sales executed before subsequent stock gains, not declines. At MS specifically, his 2 prior sells on 2025-07-17 and 2024-04-17 both resulted in positive 90-day returns (15.9% and 17.9% respectively), establishing a pattern of selling ahead of rallies rather than downturns. The fundamentals remain solid: $18.2B in latest-quarter revenue, $4.6B net income, 14.1% annual growth, and a P/E of 17.98, with current price at $183.05.

CFO Yeshaya Sharon sells 15,838 MS shares at $185.77; post-sale holdings drop to 135,304 shares (-10.5%)

Yeshaya Sharon, Morgan Stanley's CFO, executed a discretionary open-market sale of 15,838 shares at $185.77 on 2026-01-20, reducing his position from 151,142 shares to 135,304 shares. The sale occurred 1.5% above the current price of $183.05 and near the 52-week high of $191.23 (-4.3%). Examining his same-ticker history at MS, prior sells on 2025-07-17 and 2024-07-19 generated positive 90-day returns of +16.3% and +14.8% respectively—meaning the stock rose after those sales, indicating neither sale was well-timed from a bearish-signal perspective (0 of 2 prior MS sales were well-timed). The cross-ticker track record similarly shows a 0.00% well-timed rate across 2 prior sells on other stocks, with an average 90-day return of +15.6%, suggesting an historical pattern of selling before rallies rather than downturns. Morgan Stanley's fundamentals remain solid, with annual revenue growth of +14.1%, a P/E of 17.98, and latest quarterly revenue of $18.2B with net income of $4.6B. The sale appears routine in size and does not signal material concern about the company's trajectory.

Co-President SAPERSTEIN sells 30,330 shares for $5,569,085.93 at avg price $183.62

SAPERSTEIN ANDREW M, Co-President of Morgan Stanley, executed 6 separate sales on 2026-01-20 totaling 30,330 shares for $5,569,085.93, reducing his holdings by 9.8% to 280,480 shares. The blended average price of $183.62 sits near the current price of $183.05, which is 4.3% below the 52-week high of $191.23. His prior transactions at Morgan Stanley show mixed outcomes: 3 of 5 recent sells had positive 90-day returns (including +15.1%, +15.6%, and +18.7%), while 2 resulted in declines (−22.4%, −21.9%), indicating inconsistent timing performance at this ticker. Cross-ticker, his broader track record shows a 40% well-timed sell rate, suggesting his transactions are not systematically prescient. Morgan Stanley's fundamentals remain solid with $18.2B revenue, $4.6B net income, and 14.1% annual growth, though the P/E of 17.98 and the stock's recent 11.7% 90-day gain provide limited margin of safety context for this near-peak-price transaction.

Morgan Stanley CLO Eric Grossman sold 21,555 shares at $184.00; retains 168,510 shares post-transaction.

Eric Grossman, Chief Legal/Admin Officer at Morgan Stanley, sold 21,555 shares (21.6K shares) at $184.00 on 2026-01-20 for $3,966,137.24 ($4.0M), reducing his holdings by 11.3% from 190,065 shares to 168,510 shares. His prior trades at MS show mixed execution: across 5 prior sales at this ticker, 1 of 5 were well-timed at the 90-day mark, with results ranging from -22.0% (a well-timed sale in Jan 2025) to +29.0% gain (Apr 2025 sale). Stock is trading at $183.05, down 4.3% from the 52-week high of $191.23, and has gained 11.7% over the past 90 days. The company's recent financials show revenue of $18,224,000,000.00 (latest quarter) with 14.1% annual revenue growth and a P/E of 17.98. This sale reflects a substantial reduction in his direct stake but occurs near recent highs and does not materially alter his significant ongoing holdings.

MS Head of Technology & Operations sold 20,000 shares at $184.55 on 2026-01-20; holds 127.9K post-sale.

Michael A. Pizzi, Head Technology & Operations at Morgan Stanley, sold 20,000 shares (127.9K remaining) for $3.7M at $184.55, which was near the 52-week high of $191.23 (-4.3% from peak). His cross-ticker track record shows 2 prior sells with an average 90-day return of -3.4% and a well-timed rate of 50.00%, indicating mixed execution. At Morgan Stanley specifically, his prior two sells occurred on 2025-07-17 (which returned +15.7% at 90 days, poorly timed) and 2025-01-21 (which returned -22.4% at 90 days, well-timed), suggesting variable timing patterns at this ticker. The sale occurs as MS trades at $183.05, up 11.7% over 90 days, and the company shows solid fundamentals with $4.6B net income on $18.2B quarterly revenue and 14.1% annual revenue growth. The transaction size represents a 13.5% reduction from his pre-transaction holdings but remains substantial, leaving significant equity exposure.